Literature DB >> 23478586

The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.

Cigdem Soydal1, Ozlem N Kucuk, Ethem I Gecim, Sadik Bilgic, Atilla H Elhan.   

Abstract

INTRODUCTION: The aim of this study was to evaluate tumor response using fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in patients who received yttrium-90 selective internal radiation therapy (SIRT) for colorectal liver metastases. The initial and sixth-week tumor lesion glycolysis values were calculated to evaluate the success of the treatment and compare it with patient survival.
MATERIALS AND METHODS: Thirty-five patients (15 female, 20 male, mean age: 61.9 ± 9.0 years, range: 33-76 years) who received SIRT treatment for unresectable colorectal cancer liver metastases in our hospital between June 2008 and May 2011 were included in the study. All patients included in the study had liver-only or liver-dominant disease. The treatment response was evaluated by 18F-FDG PET/CT in the sixth week after treatment. Response was evaluated according to the change in total lesion glycolysis (ΔTLG). The ΔTLG was calculated using the following formula: ΔTLG=100 ×[standardized uptake value (SUV) mean1 × total functional tumor volumes (FTVs)1-SUV mean2 × FTV2]/SUV mean1 × FTV1.
RESULTS: Mean FTV1 and FTV2 values were calculated to be 235.7 ± 203 and 107.3 ± 67 mm3, respectively (P=0.04). The mean ΔTLG was 43 ± 35 (range: 0-100). Mean overall survival time was 12.7 ± 8.0 months (range: 3-31 months). The cutoff value of ΔTLG was calculated to be 26.5 using receiver operating characteristic analysis (sensitivity 64%; specificity 85%; AUC=0.717 ± 0.087, P=0.034). Patients were allocated into those having values greater than the cutoff value (group 1) and those having values lower than the cutoff value (group 2) in order to calculate the effect of ΔTLG on survival. Survival was 11.32 ± 1.18 (95% CI 9.02-13.62) months in group 2 and 20.76 ± 2.71 (95% CI 15.46-26.06) months in group 1 (P=0.016). ΔTLG was found to be a significant factor in univariate analysis (P=0.01).
CONCLUSION: An 18F-FDG PET/CT scan with calculation of ΔSUVmax3, ΔFTV, and ΔTLG before and at the sixth week after SIRT may play an important role in evaluating early tumor response and survival expectancy in these patients and help decide whether these patients should be referred to other treatment modalities or to follow-up.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23478586     DOI: 10.1097/MNM.0b013e32835f9427

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.

Authors:  Waleed Shady; Sirish Kishore; Somali Gavane; Richard K Do; Joseph R Osborne; Gary A Ulaner; Mithat Gonen; Etay Ziv; Franz E Boas; Constantinos T Sofocleous
Journal:  Eur J Radiol       Date:  2016-03-31       Impact factor: 3.528

2.  Metabolic tumor volume predicts long-term survival after transplantation for unresectable colorectal liver metastases: 15 years of experience from the SECA study.

Authors:  Harald Grut; Pål-Dag Line; Trygve Syversveen; Svein Dueland
Journal:  Ann Nucl Med       Date:  2022-10-14       Impact factor: 2.258

3.  The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases.

Authors:  Harald Grut; Svein Dueland; Pål Dag Line; Mona Elisabeth Revheim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-12       Impact factor: 9.236

Review 4.  The role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review.

Authors:  Salvatore Annunziata; Giorgio Treglia; Carmelo Caldarella; Federica Galiandro
Journal:  ScientificWorldJournal       Date:  2014-02-02

Review 5.  Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Hyun S Kim
Journal:  Oncotarget       Date:  2017-06-06

6.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  M Weber; M Lam; C Chiesa; M Konijnenberg; M Cremonesi; P Flamen; S Gnesin; L Bodei; T Kracmerova; M Luster; E Garin; K Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-11       Impact factor: 9.236

Review 7.  The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review.

Authors:  Okker D Bijlstra; Maud M E Boreel; Sietse van Mossel; Mark C Burgmans; Ellen H W Kapiteijn; Daniela E Oprea-Lager; Daphne D D Rietbergen; Floris H P van Velden; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg; J Sven D Mieog; Lioe-Fee de Geus-Oei
Journal:  Diagnostics (Basel)       Date:  2022-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.